The efficacy and safety of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 agonists in pediatric patients with type 2 diabetes: a systematic review
-
Xinyi Li
and
Luwen Shi
Abstract
Background
The incidence of type 2 diabetes mellitus (T2DM) in the pediatric population is increasing. There is a great need to develop more drugs for pediatric T2DM. Glucagon-like peptide-1 (GLP-1) agonists and dipeptidyl dipeptidase-4 (DPP-4) inhibitors have been approved for adults with T2DM and they might be effective in youths due to the similar pathogenic defects associated with T2DM. Here we aim to evaluate the efficacy and safety of GLP-1 agonists and DPP-4 inhibitors in pediatric patients with T2DM.
Contents
We performed a systematic review including trials comparing GLP-1 agonists and DPP-4 inhibitors against placebo in pediatric T2DM. This project was conducted based on the quality of reporting of meta-analyses (QUOROM) statement. Embase, PubMed, and Cochrane library were searched by two independent investigators for selecting relevant studies.
Summary and outlook
Five RCTs with a total sample size of 237 children were included. GLP-1 agonists showed superiority in glycemic improvement than placebo for pediatric T2DM. The advantage of DPP-4 inhibitors versus placebo for glycemic improvement is still unclear. GLP-1 agonists and DPP-4 inhibitors were well tolerated in pediatrics and further strictly designed trials are needed.
-
Research funding: There was no funding source for this study.
-
Author contributions: All authors contributed to the study’s conception and design. Material preparation, data collection, and analysis were performed by Xinyi Li, Tong Sun, and Xiaohui Xie. The first draft of the manuscript was written by Xinyi Li and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
-
Competing interests: The authors have no disclosures and no competing interests.
-
Informed consent: Not applicable.
-
Ethical approval: The trials included in this analysis were approved by their respective Ethics Committee.
-
Data availability: All data generated or analyzed during this study are included in this published article and its supplementary information files.
-
Code availability: Not applicable.
References
1. Saeedi, P, Petersohn, I, Salpea, P, Malanda, B, Karuranga, S, Unwin, N, et al.. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract 2019;157:107843. https://doi.org/10.1016/j.diabres.2019.107843.Search in Google Scholar PubMed
2. Pastore, I, Bolla, AM, Montefusco, L, Lunati, ME, Rossi, A, Assi, E, et al.. The impact of diabetes mellitus on cardiovascular risk onset in children and adolescents. Int J Mol Sci 2020;21:4928. https://doi.org/10.3390/ijms21144928.10.3390/ijms21144928Search in Google Scholar PubMed PubMed Central
3. Pettitt, DJ, Talton, J, Dabelea, D, Divers, J, Imperatore, G, Lawrence, JM, et al., SEARCH for Diabetes in Youth Study Group. Prevalence of diabetes in U.S. youth in 2009: the SEARCH for diabetes in youth study. Diabetes Care 2014;37:402–8. https://doi.org/10.2337/dc13-1838.Search in Google Scholar PubMed PubMed Central
4. Temneanu, OR, Trandafir, LM, Purcarea, MR. Type 2 diabetes mellitus in children and adolescents: a relatively new clinical problem within pediatric practice. J Med Life 2016;9:235–9.Search in Google Scholar
5. Zeitler, P, Arslanian, S, Fu, J, Pinhas-Hamiel, O, Reinehr, T, Tandon, N, et al.. ISPAD clinical practice consensus guidelines 2018: type 2 diabetes mellitus in youth. Pediatr Diabetes 2018;19(27 Suppl):28–46. https://doi.org/10.1111/pedi.12719.Search in Google Scholar PubMed
6. Buckley, ST, Bækdal, TA, Vegge, A, Maarbjerg, SJ, Pyke, C, Ahnfelt-Rønne, J, et al.. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med 2018;10:eaar7047. https://doi.org/10.1126/scitranslmed.aar7047.Search in Google Scholar PubMed
7. Marso, SP, Bain, SC, Consoli, A, Eliaschewitz, FG, Jódar, E, Leiter, LA, et al.. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834–44. https://doi.org/10.1056/NEJMoa1607141.Search in Google Scholar PubMed
8. Mann, JFE, Ørsted, DD, Brown-Frandsen, K, Marso, SP, Poulter, NR, Rasmussen, S, et al.. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 2017;377:839–48. https://doi.org/10.1056/NEJMoa1616011.Search in Google Scholar PubMed
9. Marso, SP, Daniels, GH, Brown-Frandsen, K, Kristensen, P, Mann, JF, Nauck, MA, et al.. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311–22. https://doi.org/10.1056/NEJMoa1603827.Search in Google Scholar PubMed PubMed Central
10. Cascone, T, William, WNJr, Weissferdt, A, Leung, CH, Lin, HY, Pataer, A, et al.. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med 2021;27:504–14. https://doi.org/10.1038/s41591-020-01224-2.Search in Google Scholar PubMed PubMed Central
11. Gao, S, Li, N, Gao, S, Xue, Q, Ying, J, Wang, S, et al.. Neoadjuvant PD-1 inhibitor (sintilimab) in NSCLC. J Thorac Oncol 2020;15:816–26. https://doi.org/10.1016/j.jtho.2020.01.017.Search in Google Scholar PubMed
12. Goldstein, BJ, Feinglos, MN, Lunceford, JK, Johnson, J, Williams-Herman, DE, Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007;30:1979–87. https://doi.org/10.2337/dc07-0627.Search in Google Scholar PubMed
13. Drucker, DJ, Nauck, MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet (London, England) 2006;368:1696–705. https://doi.org/10.1016/S0140-6736(06)69705-5.Search in Google Scholar PubMed
14. Tamborlane, WV, Barrientos-Pérez, M, Fainberg, U, Frimer-Larsen, H, Hafez, M, Hale, PM, et al.. Liraglutide in children and adolescents with type 2 diabetes. N Engl J Med 2019;381:637–46. https://doi.org/10.1056/NEJMoa1903822.Search in Google Scholar PubMed
15. Klein, DJ, Battelino, T, Chatterjee, DJ, Jacobsen, LV, Hale, PM, Arslanian, S. Liraglutide’s safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes Technol Therapeut 2014;16:679–87. https://doi.org/10.1089/dia.2013.0366.Search in Google Scholar PubMed PubMed Central
16. Fraser, IP, Neufeld, ND, Fox, LA, Kipnes, MS, Miller, TL, Zeitler, PS, et al.. A randomized clinical trial to evaluate the single-dose pharmacokinetics, pharmacodynamics, and safety of sitagliptin in pediatric patients with type 2 diabetes. Pediatr Diabetes 2019;20:48–56. https://doi.org/10.1111/pedi.12790.Search in Google Scholar PubMed
17. Tamborlane, WV, Laffel, LM, Weill, J, Gordat, M, Neubacher, D, Retlich, S, et al.. Randomized, double-blind, placebo-controlled dose-finding study of the dipeptidyl peptidase-4 inhibitor linagliptin in pediatric patients with type 2 diabetes. Pediatr Diabetes 2018;19:640–8. https://doi.org/10.1111/pedi.12616.Search in Google Scholar PubMed
18. Study to evaluate the efficacy, eafety, tolerability, and pharmacokinetics of saxagliptin as monotherapy in pediatric patients with type 2 diabetes. Available from: https://clinicaltrials.gov/show/NCT01204775 [Accessed 6 Jul 2021].Search in Google Scholar
19. Nadeau, KJ, Anderson, BJ, Berg, EG, Chiang, JL, Chou, H, Copeland, KC, et al.. Youth-onset type 2 diabetes consensus report: current status, challenges, and priorities. Diabetes Care 2016;39:1635–42. https://doi.org/10.2337/dc16-1066.Search in Google Scholar PubMed PubMed Central
20. Arslanian, S, Bacha, F, Grey, M, Marcus, MD, White, NH, Zeitler, P. Evaluation and management of youth-onset type 2 diabetes: a position statement by the American diabetes association. Diabetes Care 2018;41:2648–68. https://doi.org/10.2337/dci18-0052.Search in Google Scholar PubMed PubMed Central
21. Huelgas, RG. A clinical trial to maintain glycemic control in youth with type 2 diabetes]. Rev Clin Esp 2012;212:500. https://doi.org/10.1016/j.rce.2012.07.015.Search in Google Scholar PubMed
22. Nauck, M, Frid, A, Hermansen, K, Shah, NS, Tankova, T, Mitha, IH, et al.. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009;32:84–90. https://doi.org/10.2337/dc08-1355.Search in Google Scholar PubMed PubMed Central
23. Chadda, KR, Cheng, TS, Ong, KK. GLP-1 agonists for obesity and type 2 diabetes in children: systematic review and meta-analysis. Obes Rev 2020. https://doi.org/10.1111/obr.13177.Search in Google Scholar PubMed
Supplementary Material
The online version of this article offers supplementary material (https://doi.org/10.1515/jpem-2021-0533).
© 2022 Walter de Gruyter GmbH, Berlin/Boston
Articles in the same Issue
- Frontmatter
- Review Article
- The efficacy and safety of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 agonists in pediatric patients with type 2 diabetes: a systematic review
- Original Articles
- Triple burden of malnutrition and role of anaemia in the development of complications associated with type 1 diabetes in Indian children and youth
- Effect of obesity and excessive body fat on glycaemic control in paediatric type 1 diabetes
- Role of pan immune inflammatory value in the evaluation of hepatosteatosis in children and adolescents with obesity
- Secular trends of birth weight and its associations with obesity and hypertension among Southern Chinese children and adolescents
- Insights into the implication of obesity in hypogonadism among adolescent boys
- The association between plasma carnitines and duration of diabetic ketoacidosis treatment in children with type 1 diabetes
- Cathelicidin as a marker for subclinical cardiac changes and microvascular complications in children and adolescents with type 1 diabetes
- Developing a risk assessment tool for identifying individuals at high risk for developing insulin resistance in European adolescents: the HELENA-IR score
- Hemoglobin A1C can differentiate subjects with GCK mutations among patients suspected to have MODY
- Perceptions and use of complementary and alternative medicine in patients with precocious puberty
- Case Reports
- Infection with SARS-CoV-2 may alter the half-life of desmopressin (DDAVP) in patients with central diabetes insipidus
- Heterozygous CDC73 mutation causing hyperparathyroidism in children and adolescents: a report of 2 cases
- Wolfram syndrome in a young woman with associated hypergonadotropic hypogonadism – A case report
- Continuous glucose monitoring in an infant with panhypopituitarism having hypoglycemia on growth hormone therapy
- Severe consumptive hypothyroidism in hepatic hemangioendothelioma
- Efficacy of aromatase inhibitor therapy in a case with large cell calcifying Sertoli cell tumour-associated prepubertal gynaecomastia
Articles in the same Issue
- Frontmatter
- Review Article
- The efficacy and safety of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 agonists in pediatric patients with type 2 diabetes: a systematic review
- Original Articles
- Triple burden of malnutrition and role of anaemia in the development of complications associated with type 1 diabetes in Indian children and youth
- Effect of obesity and excessive body fat on glycaemic control in paediatric type 1 diabetes
- Role of pan immune inflammatory value in the evaluation of hepatosteatosis in children and adolescents with obesity
- Secular trends of birth weight and its associations with obesity and hypertension among Southern Chinese children and adolescents
- Insights into the implication of obesity in hypogonadism among adolescent boys
- The association between plasma carnitines and duration of diabetic ketoacidosis treatment in children with type 1 diabetes
- Cathelicidin as a marker for subclinical cardiac changes and microvascular complications in children and adolescents with type 1 diabetes
- Developing a risk assessment tool for identifying individuals at high risk for developing insulin resistance in European adolescents: the HELENA-IR score
- Hemoglobin A1C can differentiate subjects with GCK mutations among patients suspected to have MODY
- Perceptions and use of complementary and alternative medicine in patients with precocious puberty
- Case Reports
- Infection with SARS-CoV-2 may alter the half-life of desmopressin (DDAVP) in patients with central diabetes insipidus
- Heterozygous CDC73 mutation causing hyperparathyroidism in children and adolescents: a report of 2 cases
- Wolfram syndrome in a young woman with associated hypergonadotropic hypogonadism – A case report
- Continuous glucose monitoring in an infant with panhypopituitarism having hypoglycemia on growth hormone therapy
- Severe consumptive hypothyroidism in hepatic hemangioendothelioma
- Efficacy of aromatase inhibitor therapy in a case with large cell calcifying Sertoli cell tumour-associated prepubertal gynaecomastia
